Rhythm Pharmaceuticals (RYTM) Earns Daily Media Sentiment Rating of 0.21
News stories about Rhythm Pharmaceuticals (NASDAQ:RYTM) have been trending somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Rhythm Pharmaceuticals earned a news impact score of 0.21 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6501251366066 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Rhythm Pharmaceuticals (RYTM) opened at $28.91 on Tuesday. Rhythm Pharmaceuticals has a one year low of $21.38 and a one year high of $33.81.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Tuesday, November 14th. The company reported ($1.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($1.38). research analysts forecast that Rhythm Pharmaceuticals will post -1.63 EPS for the current year.
Several brokerages have issued reports on RYTM. Cowen Inc reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Morgan Stanley began coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They issued an “equal weight” rating and a $23.00 price objective for the company. Finally, Bank of America Corporation began coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They issued a “buy” rating and a $30.00 price objective for the company.
In related news, insider Bros. Advisors Lp Baker bought 885,000 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $15,045,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David P. Meeker bought 25,000 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was bought at an average price of $17.00 per share, for a total transaction of $425,000.00. The disclosure for this purchase can be found here. Insiders have purchased 1,285,000 shares of company stock worth $21,845,000 over the last 90 days.
WARNING: “Rhythm Pharmaceuticals (RYTM) Earns Daily Media Sentiment Rating of 0.21” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/rhythm-pharmaceuticals-rytm-earns-daily-media-sentiment-rating-of-0-21/1730508.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.